可參考搜尋到比較完整也容易查閱的紐西蘭外交事務部提供的TPP（跨太平洋戰略經濟夥伴關係協議，Trans-Pacific Partnership）全文（草案）：http://tpp.mfat.govt.nz/text。
有關智慧財產權的檔案：http://www.mfat.govt.nz/downloads/trade-agreement/transpacific/TPP-text/18.%20Intellectual%20Property%20Chapter.pdf。
紐西蘭針對有關該國的內容整理出概要：http://www.tpp.mfat.govt.nz/assets/docs/TPP_factsheet_Intellectual-Property.PDF。
有關智慧財產權的議題在第18章（Intellectual Property），資料參考：
https://zh.wikipedia.org/wiki/跨太平洋戰略經濟夥伴關係協議。
(updated on Nov. 26, 2015)
我國專利局提出的「跨太平洋夥伴協定(TPP)智慧財產章簡要說明與翻譯」
http://www.tipo.gov.tw/ct.asp?xItem=571002&ctNode=7127&mp=1
摘錄wikipedia的一段話，就大約知道這個約定簽下去，會影響我們的工作實務，至少會修法。
智慧財產權相關條款
從美國提案處外洩出來的TPP條文當中，含有一些關於著作權與專利權的條款，引發許多爭議。並且藥材專利可能傷害大眾用藥權利。
日本漫畫家赤松健擔憂，同人誌之類的衍生作品可能遭非法化。
TPP含有極具爭議性的ISDS（Investor-state dispute settlement）機制，該機制確保外國投資者與地主國產生爭端時交由第三方國際仲裁機構（而非地主國司法體系）進行仲裁；然而仲裁機構通常採黑箱機制，並向投資者與財團利益靠攏，而否決地主國的法律乃至立法，透過控告來阻撓地主國健康、環保法規的立法與施行。
第18章全文74頁，簡單來看，參考紐西蘭外交事務部的5頁整理，以及我認為的重點如下：
- 簽署TPP，對各國都有衝擊。
- TPP承繼TRIPS的目的與原則，TRIPS為WTO下的智慧財產權協議（Trade-related Aspects of Intellectual Property Rights）。
著作權 - 著作權（copyright）期限（延長）為70年（中華民國103年著作權法第三十條：著作財產權，除本法另有規定外，存續於著作人之生存期間及其死亡後"五十年"。），但不適用目前法規已經過期的著作。
- 著作權期限保護不能低於著作人過世後70年；如果作者非自然人（如法人），不得少於發表後70年；如果未於創作後25年內授權出版，期限仍是自創作日後70年。也就是，如果是創作日後25年內出版，就於該日起70年期限。
Article 18.63: Term of Protection for Copyright and Related Rights
Each Party shall provide that in cases in which the term of protection of a work, performance or phonogram is to be calculated:
(a) on the basis of the life of a natural person, the term shall be not less than the life of the author and 70 years after the author’s death; and
(b) on a basis other than the life of a natural person, the term shall be:
(i) not less than 70 years from the end of the calendar year of the first authorised publication of the work, performance or phonogram; or
(ii) failing such authorised publication within 25 years from the creation of the work, performance or phonogram, not less than 70 years from the end of the calendar year of the creation of the work, performance or phonogram. - TPP沒有影響平行輸入的產品，各國可以自行設定國際耗盡原則。
Article 18.11: Exhaustion of Intellectual Property Rights
Nothing in this Agreement prevents a Party from determining whether or under what conditions the exhaustion of intellectual property rights applies under its legal system. (updated on Nov. 14, 2015)
商標 - 商標註冊起保護不得低於10年，每次延展不得低於10年。
- 地理名稱標誌（Geographical Indications）可依各國國內法，但輸出時保留異議與無效的權力；另有貿易協議獲准的地理標誌的辦法，兩者具有彈性。
- 建立地理標誌保護與識別的程序：
各國提供仲裁、請願程序，並能撤銷有關地理標誌保護的措施。
Article 18.31: Administrative Procedures for the Protection or Recognition of Geographical Indications
If a Party provides administrative procedures for the protection or recognition of geographical indications, whether through a trademark or a sui generis system, that Party shall with respect to applications for that protection or petitions for that recognition:
(a) accept those applications or petitions without requiring intercession by a Party on behalf of its nationals;
(b) process those applications or petitions without imposition of overly burdensome formalities;
(c) ensure that its laws and regulations governing the filing of those applications or petitions are readily available to the public and clearly set out the procedures for these actions;
(d) make available information sufficient to allow the general public to obtain guidance concerning the procedures for filing applications or petitions and the processing of those applications or petitions in general; and allow an applicant, a petitioner, or their representative to ascertain the status of specific applications and petitions;
(e) ensure that those applications or petitions are published for opposition and provide procedures for opposing geographical indications that are the subject of applications or petitions; and
(f) provide for cancellation of the protection or recognition afforded to a geographical indication.
專利 - 任何物的發明、方法發明，只要具有新穎性、進步性與產業利用性，可賦予專利權。
- 可專利標的：已知物品的新用途、使用已知物品的新方法、使用已知物品的新流程，而非已知物品自身的使用而已。
- 法定不可專利標的：違反公眾秩序與道德的發明、人類動物或植物生命或健康或自然現象等，包括：外科手術診斷、治療、非生物與微生物的生物方法。
Article 18.37: Patentable Subject Matter
1. Subject to paragraphs 3 and 4, each Party shall make patents available for any invention, whether a product or process, in all fields of technology, provided that the invention is new, involves an inventive step and is capable of industrial application.
2. Subject to paragraphs 3 and 4 and consistent with paragraph 1, each Party confirms that patents are available for inventions claimed as at least one of the following: new uses of a known product, new methods of using a known product, or new processes of using a known product. A Party may limit those new processes to those that do not claim the use of the product as such.
3. A Party may exclude from patentability inventions, the prevention within their territory of the commercial exploitation of which is necessary to protect ordre public or morality, including to protect human, animal or plant life or health or to avoid serious prejudice to nature or the environment, provided that such exclusion is not made merely because the exploitation is prohibited by its law. A Party may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals;
(b) animals other than microorganisms, and essentially biological processes for the production of plants or animals, other than non-biological and microbiological processes.
4. A Party may also exclude from patentability plants other than microorganisms. However, consistent with paragraph 1 and subject to paragraph 3, each Party confirms that patents are available at least for inventions that are derived from plants. - 醫藥議題很重要，TPP讓會員國可以快速取得新藥，涉及醫藥檢驗時間、專利期限延長等議題。
- TPP要求各國提供5年內的藥品成份，10年農用化學品資料保護。
- TPP提出專利期限補償措施，也就是專利局造成的延遲要補償專利權人，如美國PTA。
- 專利期限補償的延遲要件（對於核准專利）如：(1)未於申請日後五年內獲准；(2)未於提出實際審查請求後3年內獲准；(3)因為申請人造成的延遲不得要求延長專利期限。Article 18.46: Patent Term Adjustment for Patent Office Delays
1. Each Party shall make best efforts to process patent applications in an efficient and timely manner, with a view to avoiding unreasonable or unnecessary delays.
2. A Party may provide procedures for a patent applicant to request to expedite the examination of its patent application.
3. If there are unreasonable delays in a Party’s issuance of patents, that Party shall provide the means to, and at the request of the patent owner shall, adjust the term of the patent to compensate for such delays.
4. For the purposes of this Article, an unreasonable delay at least shall include a delay in the issuance of a patent of more than five years from the date of filing of the application in the territory of the Party, or three years after a request for examination of the application has been made, whichever is later. A Party may exclude, from the determination of such delays, periods of time that do not occur during the processing of, or the examination of, the patent application by the granting authority; periods of time that are not directly attributable to the granting authority; as well as periods of time that are attributable to the patent applicant. - TPP要求各國政府在藥品上市前通知藥品專利擁有者知道藥品安全檢驗批准，可以讓專利權人主張權利，包括禁令。
- TPP要求各國政府提供專利藥過期資訊，讓製藥廠可以使用過期專利藥（學名藥）。
- TPP沒有禁止學名藥品出口。
- TPP要求專利優惠期有12個月，這不同我國現行專利法。
- 各國海關有權延遲侵權產品進口。
- 針對醫藥專利不合理的期限減縮：
要求提供最好而有效率的檢驗時間，避免不當延遲；提供不合理延遲的專利期限補償。
Article 18.48: Patent Term Adjustment for Unreasonable Curtailment
1. Each Party shall make best efforts to process applications for marketing approval of pharmaceutical products in an efficient and timely manner, with a view to avoiding unreasonable or unnecessary delays.
2. With respect to a pharmaceutical product that is subject to a patent, each Party shall make available an adjustment of the patent term to compensate the patent owner for unreasonable curtailment of the effective patent term as a result of the marketing approval process.
3. For greater certainty, in implementing the obligations of this Article, each Party may provide for conditions and limitations, provided that the Party continues to give effect to this Article.
4. With the objective of avoiding unreasonable curtailment of the effective patent term, a Party may adopt or maintain procedures that expedite the processing of marketing approval applications.
看似對大家好的或公平的協議，但是對於美國這種專利、著作權、軟硬體技術輸出大國來說，各會員國只能接受，並在相關產業增加許多使用成本，至少很多音樂、著作、電影都被保護得好好的。這會是一個文化衝擊，聲稱「文創」很厲害的台灣，如果真的很厲害，應該是好事。
醫藥方面，美國也是生物藥物科技的大國，這個協議充滿保護色彩，會讓不少醫藥成本上升，因為專利藥成本墊高，學名藥又被延遲，不過會得到最新卻很貴的藥品。
一般專利期限補償，這是好事，衝擊的是專利審查單位。
Ron
沒有留言:
張貼留言